Deficient immune response following SARS-CoV-2 vaccination in patients with hepatobiliary carcinoma: a forgotten, vulnerable group of patients?
Background: Data on immune response rates following vaccination for SARS-CoV-2 in patients with hepatobiliary carcinoma (HBC) are rare. However, impaired immunogenicity must be expected due to the combination of chronic liver diseases (CLD) with malignancy and anticancer treatment. Methods: In thi...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-05-01
|
| Series: | Liver Cancer |
| Online Access: | https://beta.karger.com/Article/FullText/529608 |